All
Abbott Forwards Project Using Process Analytical Technology
April 25th 2007Interphex2007, New York, NY (Apr. 25)-One of the challenges facing pharmaceutical manufacturers is how to implement process analytical technology (PAT) into their commercial manufacturing processes. Michael Abad, engineering section manager, Abbott Laboratories shared insight from a project within Abbott in his presentation "Engineering for PAT" at Interphex today.
A Call for Flexible Manufacturing Capacity for Vaccine Production
April 25th 2007Interphex2007, New York, NY (Apr. 25)-As governments begin to contemplate the possibility of biological terrorism or a pandemic event, a new problem begins to emerge: in the case of a pandemic or an attack, even if a vaccine or treatment exists, how could it be produced in sufficient numbers to prevent the deaths of millions of people? That question was addressed in at the conference session, "Responding to Bioterrorism and Pandemic Events: A Case for Development of Flexible Manufacturing Space for Vaccine Production," at Interphex today.
Analytics Key to Forging Collaborative Models Between Product Development and Manufacturing
April 25th 2007Interphex2007 (Apr. 25)-As the pharmaceutical industry moves to a risk-based approach in manufacturing, analytics will play a critical role in not only meeting regulatory requirements but also in building needed collaboration between product development and manufacturing groups.
Resolving Powder Flow Problems
April 25th 2007Interphex, New York, NY (Apr. 25)-Problems caused by the presence and movement of air in pharmaceutical powders are increasing, and many times these problems can be avoided. James K. Prescott, senior consultant at Jenike & Johanson reviewed these problems in his presentation, "Interstitial Air Effect on Powder Flow," at the Wednesday conference session at Interphex.
21 CFR Part 11 Revision Delayed, But Moves Forward
April 24th 2007Interphex, New York, NY (Apr. 24)-Although the second revision of 21 CFR Part 11, the Electronic Records and Signatures Rule, has not been finalized, there is some progress being made. This was the topic of a presentation given by John English, manager of computer system validation for BE&K BioPharm at today?s Interphex Pharmaceutical Manufacturing Conference and Exhibition.
Approaches for Successful Project Management Highlighted at Interphex
April 24th 2007Interphex2007, New York, NY (Apr. 24)-Effective project management is critical for successful outsourcing between a pharmaceutical company or sponsor and a contract manufacturing organization (CMO), and the strategies for such success was highlighted at the Interphex2007 Conference and Exhibition.
Company Views on Evolution and Advances in Medical Devices Discussed
April 24th 2007Interphex2007, New York, NY (Apr. 24)?Reflecting the advances of the pharmaceutical industry as a whole and the success of individual companies in the growth of the pharmaceutical industry, Bill Cook, founder and CEO of Cook Group Inc. in a keynote address at Interphex2007 described the benefits of keeping a company private and touched on the future of medical devices.
E-pedigree Federal and State Requirements Presented
April 24th 2007Interphex, New York, NY (Apr. 24)-Radio-frequency identification (RFID) technology is an increasingly important tool in the pharmaceutical supply chain. Paul Rudolph of Arent Fox PLLC gave the first of several talks on RFID and e-pedigree at Interphex today in his presentation, "Pedigrees: Update on Federal and State Regulation and Effect on RFID Tagging of Products."
FDA Licenses Sanofi-Pasteur's H5N1 Vaccine
April 19th 2007Lyon, France (Apr. 17)-Sanofi Pasteur, the vaccine division of the Sanofi-Aventis Group, announced that the US Food and Drug Administration has licensed its H5N1 vaccine, making it the first avian-influenza vaccine for humans in the United States.
Patheon Restructures Canadian Manufacturing Operations
April 19th 2007Toronto (Apr. 17)-Patheon, Inc. plans to restructure its current network of six pharmaceutical manufacturing facilities in southern Ontario, Canada as part of its strategy to focus on manufacturing prescription pharmaceutical products and to improve its profitability.
GlaxoSmithKline Plans Investment in Irish Manufacturing Facility
April 5th 2007London (Mar. 29)-GlaxoSmithKline (GSK) plans to invest EUR 250 million ($334 million) at its production site at Currabinny, County Cork, Ireland over the next five years, according to a release issued by the Irish Development Agency (IDA Ireland, Dublin).
Lonza Breaks Ground on Biologics Manufacturing Facility in Singapore
April 5th 2007Singapore (Mar. 29)-The contract manufacturing organization Lonza Group (Basel, Switzerland) and Bio*One Capital (Singapore) broke ground for their large-scale commercial mammalian cell-culture manufacturing facility at Tuas Biomedical Park in Singapore.
EC Plans Directive on GMPs for Excipients
April 5th 2007Brussels, Belgium (Mar. 22)-The European Commission?s (EC) Directorate-General for Enterprise and Industry (Brussels, Belgium) is asking manufacturers, distributors, and users of human-pharmaceutical excipients to participate in an online questionnaire on the effect of various policy options. Responses will be used to prepare a directive on good manufacturing practices (GMPs) for certain excipients.
India's Pharmaceutical Machine Manufacturers: From Imitation to Innovation
April 2nd 2007Indian pharmaceutical machine manufacturers (IPMMs) are exceptional among their foreign counterparts. Historically similar to the Chinese with regard to copycat practices, patent infringements, and substandard quality, the IPMMs have made great strides in innovation and collaboration to break free from the shackles of this paradigm.